24
Participants
Start Date
August 17, 2018
Primary Completion Date
July 25, 2019
Study Completion Date
July 25, 2019
AMG 397
AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
Dexamethasone
Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
Azacitidine
Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
Royal Prince Alfred Hospital, Camperdown
The Alfred Hospital, Melbourne
Princess Alexandra Hospital, Woolloongabba
Memorial Sloan Kettering Cancer Center, New York
Alexandra Hospital, Athens
Institut Paoli Calmettes, Marseille
Roswell Park Cancer Institute, Buffalo
University of Maryland Greenebaum Cancer Center, Baltimore
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo
Mayo Clinic Florida, Jacksonville
University of Alabama at Birmingham, Birmingham
Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi, Bologna
Froedtert and Med College Wisconsin, Milwaukee
Mayo Clinic Rochester, Rochester
Washington University, St Louis
University of Kansas Cancer Center, Westwood
University of Texas MD Anderson Cancer Center, Houston
Mayo Clinic Arizona, Phoenix
Institut Gustave Roussy, Villejuif
Dana Farber Cancer Institute, Boston
Ogaki Municipal Hospital, Ogaki-shi
Lead Sponsor
Amgen
INDUSTRY